Questionnaire and Laboratory Data on Vitiligo Vulgaris

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Beth Israel Medical Center
Information provided by (Responsible Party):
St. Luke's-Roosevelt Hospital Center
ClinicalTrials.gov Identifier:
NCT01206374
First received: September 20, 2010
Last updated: May 13, 2014
Last verified: May 2014

September 20, 2010
May 13, 2014
August 2010
September 2014   (final data collection date for primary outcome measure)
Quality of life disturbances in people with vitiligo [ Time Frame: point prevalence ] [ Designated as safety issue: No ]
dermatology life quality indices were you used and correlated with location of disease
Not Provided
Complete list of historical versions of study NCT01206374 on ClinicalTrials.gov Archive Site
self-reporting of vitiligo disease symptoms and history [ Time Frame: single survey ] [ Designated as safety issue: No ]
Correlation of the patient survey response with chart documentation was performed.
Not Provided
Not Provided
Not Provided
 
Questionnaire and Laboratory Data on Vitiligo Vulgaris
Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris

Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals). While genes have been identified that are thought to be required for development of vitiligo, only 5-10% of relatives develop disease. The triggers for disease onset have not yet been identified. The intent of this study is to research trends in laboratory data, social and medical history that may be contributory to vitiligo onset, location of disease, course of illness and response to therapy.

Patients who participate in this study will be asked to complete a survey and have blood/ laboratory testing performed that relates or may relate to the diagnosis of vitiligo.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

All patients willing to sign consent, complete questionnaire and/ or laboratory studies.

Vitiligo Vulgaris
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
300
September 2014
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of Vitiligo Vulgaris
  • Ability to sign consent

Exclusion Criteria:

  • Pregnant
  • Inability to sign consent
  • Inability to complete questionnaire
Both
Not Provided
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01206374
10-027SLRHC
Yes
St. Luke's-Roosevelt Hospital Center
St. Luke's-Roosevelt Hospital Center
Beth Israel Medical Center
Principal Investigator: Nanette Silverberg, MD StLukesNY
St. Luke's-Roosevelt Hospital Center
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP